ALB and head and neck cancer: Pembrolizumab was economically unavailable for this patient, so we recommended Toripalimab to him, a recombinant, humanized programmed death receptor-1 monoclonal antibody that had been approved in recurrent/metastatic nasopharyngeal carcinoma in 2021 in China.[13,14] In this case, according to the chemotherapy regimen of head and neck cancer, we selected the less toxic agents (albumin-paclitaxel that did not require corticosteroid pretreatment combined with cisplatin).[15] After treatment, the patient achieved a clinical partial response, and the quality of life significantly improved.